Gastric Electrical Stimulation for Gastroparesis

(HEAL Trial)

TL
Overseen ByThomas L Abell, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

Gastroparesis is a disorder characterized by delayed gastric emptying and symptoms including nausea, vomiting, and abdominal pain. Gastric electrical stimulation (GES) using the implanted Enterra™ neurostimulator is FDA-approved to treat nausea and vomiting but its impact on abdominal pain has not been well studied. This study evaluates whether alternative programming parameters of the Enterra™ device can reduce abdominal pain in patients with gastroparesis. Participants with an existing Enterra™ device will be randomized to one of three stimulation settings and followed for assessment of pain, gastrointestinal symptoms, quality of life, and medication use.

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with gastroparesis.
Implanted Enterra™ device for at least 8 weeks prior to enrollment
I have had daily stomach pain for over 2 months.
See 3 more

Exclusion Criteria

Other medical conditions that would interfere with study participation
I do not have severe constipation or uncontrolled diabetes.
Daily opioid use
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2 weeks
1 visit (in-person)

Run-in

Participants complete a two-week run-in period using their baseline clinical device settings

2 weeks
1 visit (in-person)

Randomized Treatment

Participants are randomly assigned to one of three gastric electrical stimulation parameter sets and remain on their assigned settings for eight weeks

8 weeks
4 visits (in-person)

Follow-up

Participants may select their preferred settings for an additional eight-week follow-up period

8 weeks
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Gastric Electrical Stimulation

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Active Control

Group I: Special Parameter GESExperimental Treatment1 Intervention
Group II: Modified Enterra ParametersExperimental Treatment1 Intervention
Group III: Nominal GES ParametersActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Louisville

Lead Sponsor

Trials
353
Recruited
76,400+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+